{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T21:58:03Z","timestamp":1776463083981,"version":"3.51.2"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose of Review<\/jats:title>\n                <jats:p>Remarkable reductions in cardiovascular morbidity and mortality have been achieved in recent decades through the widespread use of \u2018small-molecule\u2019 hypolipidaemic drugs such as statins and ezetimibe. An alternative approach is to perturb the production of proteins through ribonucleic acid (RNA) silencing, leading to long-lasting knock-down of specific biological molecules. This review describes the scientific basis of RNA silencing, and critically evaluates the evidence relating to inclisiran, a small interfering RNA against proprotein convertase subtilisin kexin 9 (PCSK9).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Recent Findings<\/jats:title>\n                <jats:p>Pooled analysis of three recent ORION trials has demonstrated that twice-yearly administration of inclisiran reduces LDL-C by 50% in a range of patient groups, with only mild adverse effects.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Summary<\/jats:title>\n                <jats:p>Inclisiran provides safe, effective and long-lasting reductions in PCSK9 and LDL-C. The results of the phase-3 ORION-4 outcomes study are eagerly awaited. Further promising RNA silencing technologies have the potential to improve the management of dyslipidaemia.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11883-021-00968-7","type":"journal-article","created":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T08:05:11Z","timestamp":1630483511000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["RNA Silencing in the Management of Dyslipidemias"],"prefix":"10.1007","volume":"23","author":[{"given":"Neil C.","family":"Henney","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maciej","family":"Banach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6763-1489","authenticated-orcid":false,"given":"Peter E.","family":"Penson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,9,1]]},"reference":[{"issue":"11","key":"968_CR1","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1111\/bcp.14359","volume":"86","author":"PE Penson","year":"2020","unstructured":"Penson PE. Spotlight Commentary: what\u2019s new in lipid-lowering pharmacology? Integrating basic and clinical research to improve patient outcomes. Br J Clin Pharmacol. 2020;86(11):2111\u20133. https:\/\/doi.org\/10.1111\/bcp.14359.","journal-title":"Br J Clin Pharmacol"},{"issue":"10059","key":"968_CR2","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1016\/S0140-6736(16)31357-5","volume":"388","author":"R Collins","year":"2016","unstructured":"Collins R, Reith C, Emberson J, Armitage J, Baigent C, Blackwell L, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016;388(10059):2532\u201361. https:\/\/doi.org\/10.1016\/S0140-6736(16)31357-5.","journal-title":"Lancet"},{"issue":"25","key":"968_CR3","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","volume":"372","author":"CP Cannon","year":"2015","unstructured":"Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387\u201397. https:\/\/doi.org\/10.1056\/NEJMoa1410489.","journal-title":"N Engl J Med"},{"issue":"2","key":"968_CR4","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1080\/13543784.2017.1280458","volume":"26","author":"P Penson","year":"2017","unstructured":"Penson P, McGowan M, Banach M. Evaluating bempedoic acid for the treatment of hyperlipidaemia. Expert Opin Investig Drugs. 2017;26(2):251\u20139. https:\/\/doi.org\/10.1080\/13543784.2017.1280458.","journal-title":"Expert Opin Investig Drugs"},{"issue":"24","key":"968_CR5","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1093\/eurheartj\/ehz962","volume":"41","author":"J Boren","year":"2020","unstructured":"Boren J, Chapman MJ, Krauss RM, Packard CJ, Bentzon JF, Binder CJ, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2020;41(24):2313\u201330. https:\/\/doi.org\/10.1093\/eurheartj\/ehz962.","journal-title":"Eur Heart J"},{"key":"968_CR6","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459\u201372. https:\/\/doi.org\/10.1093\/eurheartj\/ehx144. This paper provides a comprehensive overview of the evidence supporting the causal nature of LDL-C in atherosclerotic cardiovascular disease.","DOI":"10.1093\/eurheartj\/ehx144"},{"issue":"1","key":"968_CR7","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1186\/s12916-020-01792-7","volume":"18","author":"PE Penson","year":"2020","unstructured":"Penson PE, Pirro M, Banach M. LDL-C: lower is better for longer-even at low risk. BMC Med. 2020;18(1):320. https:\/\/doi.org\/10.1186\/s12916-020-01792-7.","journal-title":"BMC Med"},{"key":"968_CR8","doi-asserted-by":"publisher","first-page":"105499","DOI":"10.1016\/j.phrs.2021.105499","volume":"166","author":"M Banach","year":"2021","unstructured":"Banach M, Penson PE, Vrablik M, Bunc M, Dyrbus K, Fedacko J, et al. Optimal use of lipid-lowering therapy after acute coronary syndromes: a position paper endorsed by the International Lipid Expert Panel (ILEP). Pharmacol Res. 2021;166:105499. https:\/\/doi.org\/10.1016\/j.phrs.2021.105499.","journal-title":"Pharmacol Res"},{"issue":"5","key":"968_CR9","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.jacc.2020.05.070","volume":"76","author":"JL Katzmann","year":"2020","unstructured":"Katzmann JL, Packard CJ, Chapman MJ, Katzmann I, Laufs U. Targeting RNA with antisense oligonucleotides and small interfering RNA: JACC state-of-the-art review. J Am Coll Cardiol. 2020;76(5):563\u201379. https:\/\/doi.org\/10.1016\/j.jacc.2020.05.070.","journal-title":"J Am Coll Cardiol"},{"key":"968_CR10","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1093\/eurheartj\/ehz747.0310","volume":"40","author":"P Penson","year":"2019","unstructured":"Penson P, Toth P, Mikhailidis D, Ezhov M, Fras Z, Mitchenko O, et al. Step by step diagnosis and management of statin intolerance: position paper from an international lipid expert panel. Eur Heart J. 2019;40:312. https:\/\/doi.org\/10.1093\/eurheartj\/ehz747.0310.","journal-title":"Eur Heart J"},{"issue":"6","key":"968_CR11","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1002\/jcsm.12344","volume":"9","author":"PE Penson","year":"2018","unstructured":"Penson PE, Mancini GBJ, Toth PP, Martin SS, Watts GF, Sahebkar A, et al. Introducing the \u201cDrucebo\u201d effect in statin therapy: a systematic review of studies comparing reported rates of statin-associated muscle symptoms, under blinded and open-label conditions. J Cachexia Sarcopenia Muscle. 2018;9(6):1023\u201333. https:\/\/doi.org\/10.1002\/jcsm.12344.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"2","key":"968_CR12","doi-asserted-by":"publisher","first-page":"542","DOI":"10.5114\/aoms\/132304","volume":"17","author":"M Banach","year":"2021","unstructured":"Banach M, Penson PE. Drucebo effect - the challenge we should all definitely face! Arch Med Sci. 2021;17(2):542\u20133. https:\/\/doi.org\/10.5114\/aoms\/132304.","journal-title":"Arch Med Sci"},{"issue":"11","key":"968_CR13","doi-asserted-by":"publisher","first-page":"e2025675","DOI":"10.1001\/jamanetworkopen.2020.25675","volume":"3","author":"M Banach","year":"2020","unstructured":"Banach M, Penson PE. Statins and LDL-C in secondary prevention-so much progress, So Far to Go. JAMA Netw Open. 2020;3(11):e2025675. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.25675.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"968_CR14","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1093\/cvr\/cvy198","volume":"115","author":"P Penson","year":"2019","unstructured":"Penson P, Long DL, Howard G, Howard VJ, Jones SR, Martin SS, et al. Associations between cardiovascular disease, cancer, and very low high-density lipoprotein cholesterol in the REasons for Geographical and Racial Differences in Stroke (REGARDS) study. Cardiovasc Res. 2019;115(1):204\u201312. https:\/\/doi.org\/10.1093\/cvr\/cvy198.","journal-title":"Cardiovasc Res"},{"issue":"40","key":"968_CR15","doi-asserted-by":"publisher","first-page":"3641","DOI":"10.1093\/eurheartj\/ehy533","volume":"39","author":"PE Penson","year":"2018","unstructured":"Penson PE, Long DL, Howard G, Toth PP, Muntner P, Howard VJ, et al. Associations between very low concentrations of low density lipoprotein cholesterol, high sensitivity C-reactive protein, and health outcomes in the Reasons for Geographical and Racial Differences in Stroke (REGARDS) study. Eur Heart J. 2018;39(40):3641\u201353. https:\/\/doi.org\/10.1093\/eurheartj\/ehy533.","journal-title":"Eur Heart J"},{"issue":"12","key":"968_CR16","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","volume":"377","author":"PM Ridker","year":"2017","unstructured":"Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119\u201331. https:\/\/doi.org\/10.1056\/NEJMoa1707914.","journal-title":"N Engl J Med"},{"issue":"7","key":"968_CR17","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s11883-021-00932-5","volume":"23","author":"M Banach","year":"2021","unstructured":"Banach M, Penson PE. Colchicine and cardiovascular outcomes: a critical appraisal of recent studies. Curr Atheroscler Rep. 2021;23(7):32. https:\/\/doi.org\/10.1007\/s11883-021-00932-5.","journal-title":"Curr Atheroscler Rep"},{"issue":"9","key":"968_CR18","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/j.jacc.2020.12.058","volume":"77","author":"RS Wright","year":"2021","unstructured":"\u2022\u2022 Wright RS, Ray KK, Raal FJ, Kallend DG, Jaros M, Koenig W, et al. Pooled patient-level analysis of inclisiran trials in patients with familial hypercholesterolemia or atherosclerosis. J Am Coll Cardiol. 2021;77(9):1182\u201393. https:\/\/doi.org\/10.1016\/j.jacc.2020.12.058. This paper provides a patient-level pooled analysis of clinical trials of inclisiran.","journal-title":"J Am Coll Cardiol"},{"key":"968_CR19","doi-asserted-by":"publisher","DOI":"10.1093\/eurjpc\/zwaa145","author":"M Banach","year":"2020","unstructured":"Banach M, Penson PE. Cellular senescence, telomeres, and cardiovascular risk in familial hypercholesterolaemia. Eur J Prev Cardiol. 2020. https:\/\/doi.org\/10.1093\/eurjpc\/zwaa145.","journal-title":"Eur J Prev Cardiol"},{"key":"968_CR20","doi-asserted-by":"publisher","first-page":"104891","DOI":"10.1016\/j.phrs.2020.104891","volume":"158","author":"M Banach","year":"2020","unstructured":"Banach M, Penson PE, Fras Z, Vrablik M, Pella D, Reiner Z, et al. Brief recommendations on the management of adult patients with familial hypercholesterolemia during the COVID-19 pandemic. Pharmacol Res. 2020;158:104891. https:\/\/doi.org\/10.1016\/j.phrs.2020.104891.","journal-title":"Pharmacol Res"},{"issue":"1","key":"968_CR21","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1177\/2047487319870342","volume":"27","author":"M Banach","year":"2020","unstructured":"Banach M, Penson PE. Genetic testing in familial hypercholesterolaemia: what does it add? Eur J Prev Cardiol. 2020;27(1):105\u20136. https:\/\/doi.org\/10.1177\/2047487319870342.","journal-title":"Eur J Prev Cardiol"},{"issue":"3","key":"968_CR22","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1093\/cvr\/cvy301","volume":"115","author":"M Banach","year":"2019","unstructured":"\u2022\u2022 Banach M, Penson PE. What have we learned about lipids and cardiovascular risk from PCSK9 inhibitor outcome trials: ODYSSEY and FOURIER? Cardiovasc Res. 2019;115(3):e26\u201331. https:\/\/doi.org\/10.1093\/cvr\/cvy301. This paper summarised and critically discusses clinical evidence from randomised-controlled trials of monoclonal antibody PCSK9 inhibitors.","journal-title":"Cardiovasc Res"},{"issue":"1","key":"968_CR23","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.jacl.2019.11.001","volume":"14","author":"K Dyrbus","year":"2020","unstructured":"Dyrbus K, Gasior M, Penson P, Ray KK, Banach M. Inclisiran-new hope in the management of lipid disorders? J Clin Lipidol. 2020;14(1):16\u201327. https:\/\/doi.org\/10.1016\/j.jacl.2019.11.001.","journal-title":"J Clin Lipidol"},{"issue":"1","key":"968_CR24","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1609243","volume":"376","author":"K Fitzgerald","year":"2017","unstructured":"Fitzgerald K, White S, Borodovsky A, Bettencourt BR, Strahs A, Clausen V, et al. A highly durable RNAi therapeutic inhibitor of PCSK9. N Engl J Med. 2017;376(1):41\u201351. https:\/\/doi.org\/10.1056\/NEJMoa1609243.","journal-title":"N Engl J Med"},{"issue":"6669","key":"968_CR25","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/35888","volume":"391","author":"A Fire","year":"1998","unstructured":"Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 1998;391(6669):806\u201311. https:\/\/doi.org\/10.1038\/35888.","journal-title":"Nature"},{"key":"968_CR26","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1146\/annurev-med-012017-043332","volume":"70","author":"XM Anguela","year":"2019","unstructured":"Anguela XM, High KA. Entering the modern era of gene therapy. Annu Rev Med. 2019;70:273\u201388. https:\/\/doi.org\/10.1146\/annurev-med-012017-043332.","journal-title":"Annu Rev Med"},{"issue":"2","key":"968_CR27","doi-asserted-by":"publisher","first-page":"87","DOI":"10.4068\/cmj.2020.56.2.87","volume":"56","author":"YK Kim","year":"2020","unstructured":"Kim YK. RNA therapy: current status and future potential. Chonnam Med J. 2020;56(2):87\u201393. https:\/\/doi.org\/10.4068\/cmj.2020.56.2.87.","journal-title":"Chonnam Med J"},{"issue":"10","key":"968_CR28","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/s41573-020-0075-7","volume":"19","author":"TC Roberts","year":"2020","unstructured":"Roberts TC, Langer R, Wood MJA. Advances in oligonucleotide drug delivery. Nat Rev Drug Discov. 2020;19(10):673\u201394. https:\/\/doi.org\/10.1038\/s41573-020-0075-7.","journal-title":"Nat Rev Drug Discov"},{"issue":"6836","key":"968_CR29","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/35078107","volume":"411","author":"SM Elbashir","year":"2001","unstructured":"Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 2001;411(6836):494\u20138. https:\/\/doi.org\/10.1038\/35078107.","journal-title":"Nature"},{"issue":"2","key":"968_CR30","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/nrd2742","volume":"8","author":"KA Whitehead","year":"2009","unstructured":"Whitehead KA, Langer R, Anderson DG. Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov. 2009;8(2):129\u201338. https:\/\/doi.org\/10.1038\/nrd2742.","journal-title":"Nat Rev Drug Discov"},{"issue":"11","key":"968_CR31","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1038\/nmat3765","volume":"12","author":"R Kanasty","year":"2013","unstructured":"Kanasty R, Dorkin JR, Vegas A, Anderson D. Delivery materials for siRNA therapeutics. Nat Mater. 2013;12(11):967\u201377. https:\/\/doi.org\/10.1038\/nmat3765.","journal-title":"Nat Mater"},{"issue":"1","key":"968_CR32","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41392-020-0207-x","volume":"5","author":"B Hu","year":"2020","unstructured":"Hu B, Zhong L, Weng Y, Peng L, Huang Y, Zhao Y, et al. Therapeutic siRNA: state of the art. Signal Transduct Target Ther. 2020;5(1):101. https:\/\/doi.org\/10.1038\/s41392-020-0207-x.","journal-title":"Signal Transduct Target Ther"},{"issue":"33","key":"968_CR33","doi-asserted-by":"publisher","first-page":"11915","DOI":"10.1073\/pnas.0805434105","volume":"105","author":"M Frank-Kamenetsky","year":"2008","unstructured":"Frank-Kamenetsky M, Grefhorst A, Anderson NN, Racie TS, Bramlage B, Akinc A, et al. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc Natl Acad Sci U S A. 2008;105(33):11915\u201320. https:\/\/doi.org\/10.1073\/pnas.0805434105.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"968_CR34","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1089\/nat.2018.0721","volume":"28","author":"JA Kulkarni","year":"2018","unstructured":"Kulkarni JA, Cullis PR, van der Meel R. Lipid nanoparticles enabling gene therapies: from concepts to clinical utility. Nucleic Acid Ther. 2018;28(3):146\u201357. https:\/\/doi.org\/10.1089\/nat.2018.0721.","journal-title":"Nucleic Acid Ther"},{"issue":"10","key":"968_CR35","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1038\/nbt1339","volume":"25","author":"C Wolfrum","year":"2007","unstructured":"Wolfrum C, Shi S, Jayaprakash KN, Jayaraman M, Wang G, Pandey RK, et al. Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat Biotechnol. 2007;25(10):1149\u201357. https:\/\/doi.org\/10.1038\/nbt1339.","journal-title":"Nat Biotechnol"},{"issue":"32","key":"968_CR36","doi-asserted-by":"publisher","first-page":"12982","DOI":"10.1073\/pnas.0703778104","volume":"104","author":"DB Rozema","year":"2007","unstructured":"Rozema DB, Lewis DL, Wakefield DH, Wong SC, Klein JJ, Roesch PL, et al. Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes. Proc Natl Acad Sci U S A. 2007;104(32):12982\u20137. https:\/\/doi.org\/10.1073\/pnas.0703778104.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"968_CR37","doi-asserted-by":"publisher","first-page":"5216","DOI":"10.1016\/j.bmc.2008.03.017","volume":"16","author":"O Khorev","year":"2008","unstructured":"Khorev O, Stokmaier D, Schwardt O, Cutting B, Ernst B. Trivalent, Gal\/GalNAc-containing ligands designed for the asialoglycoprotein receptor. Bioorg Med Chem. 2008;16(9):5216\u201331. https:\/\/doi.org\/10.1016\/j.bmc.2008.03.017.","journal-title":"Bioorg Med Chem"},{"issue":"49","key":"968_CR38","doi-asserted-by":"publisher","first-page":"16958","DOI":"10.1021\/ja505986a","volume":"136","author":"JK Nair","year":"2014","unstructured":"Nair JK, Willoughby JL, Chan A, Charisse K, Alam MR, Wang Q, et al. Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing. J Am Chem Soc. 2014;136(49):16958\u201361. https:\/\/doi.org\/10.1021\/ja505986a.","journal-title":"J Am Chem Soc"},{"issue":"11","key":"968_CR39","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1001\/jamacardio.2019.3502","volume":"4","author":"KK Ray","year":"2019","unstructured":"Ray KK, Stoekenbroek RM, Kallend D, Nishikido T, Leiter LA, Landmesser U, et al. Effect of 1 or 2 doses of inclisiran on low-density lipoprotein cholesterol levels: one-year follow-up of the ORION-1 randomized clinical trial. JAMA Cardiol. 2019;4(11):1067\u201375. https:\/\/doi.org\/10.1001\/jamacardio.2019.3502.","journal-title":"JAMA Cardiol"},{"issue":"22","key":"968_CR40","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1161\/CIRCULATIONAHA.119.044431","volume":"141","author":"GK Hovingh","year":"2020","unstructured":"Hovingh GK, Lepor NE, Kallend D, Stoekenbroek RM, Wijngaard PLJ, Raal FJ. Inclisiran durably lowers low-density lipoprotein cholesterol and proprotein convertase subtilisin\/kexin type 9 expression in homozygous familial hypercholesterolemia: the ORION-2 pilot study. Circulation. 2020;141(22):1829\u201331. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.044431.","journal-title":"Circulation"},{"issue":"1","key":"968_CR41","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.mayocp.2019.08.021","volume":"95","author":"RS Wright","year":"2020","unstructured":"Wright RS, Collins MG, Stoekenbroek RM, Robson R, Wijngaard PLJ, Landmesser U, et al. Effects of renal impairment on the pharmacokinetics, efficacy, and safety of inclisiran: an analysis of the ORION-7 and ORION-1 studies. Mayo Clin Proc. 2020;95(1):77\u201389. https:\/\/doi.org\/10.1016\/j.mayocp.2019.08.021.","journal-title":"Mayo Clin Proc"},{"issue":"16","key":"968_CR42","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1056\/NEJMoa1913805","volume":"382","author":"FJ Raal","year":"2020","unstructured":"Raal FJ, Kallend D, Ray KK, Turner T, Koenig W, Wright RS, et al. Inclisiran for the treatment of heterozygous familial hypercholesterolemia. N Engl J Med. 2020;382(16):1520\u201330. https:\/\/doi.org\/10.1056\/NEJMoa1913805.","journal-title":"N Engl J Med"},{"issue":"16","key":"968_CR43","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","volume":"382","author":"KK Ray","year":"2020","unstructured":"Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Raal FJ, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020;382(16):1507\u201319. https:\/\/doi.org\/10.1056\/NEJMoa1912387.","journal-title":"N Engl J Med"},{"issue":"9911","key":"968_CR44","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/s0140-6736(13)61914-5","volume":"383","author":"K Fitzgerald","year":"2014","unstructured":"Fitzgerald K, Frank-Kamenetsky M, Shulga-Morskaya S, Liebow A, Bettencourt BR, Sutherland JE, et al. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin\/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial. Lancet. 2014;383(9911):60\u20138. https:\/\/doi.org\/10.1016\/s0140-6736(13)61914-5.","journal-title":"Lancet"},{"issue":"1","key":"968_CR45","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1093\/cvr\/cvaa077","volume":"117","author":"U Landmesser","year":"2021","unstructured":"Landmesser U, Haghikia A, Leiter LA, Wright RS, Kallend D, Wijngaard P, et al. Effect of inclisiran, the small-interfering RNA against proprotein convertase subtilisin\/kexin type 9, on platelets, immune cells, and immunological biomarkers: a pre-specified analysis from ORION-1. Cardiovasc Res. 2021;117(1):284\u201391. https:\/\/doi.org\/10.1093\/cvr\/cvaa077.","journal-title":"Cardiovasc Res"},{"issue":"1","key":"968_CR46","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1093\/cvr\/cvaa139","volume":"117","author":"AL Catapano","year":"2021","unstructured":"Catapano AL, Pirillo A, Norata GD. Insights from ORION studies: focus on inclisiran safety. Cardiovasc Res. 2021;117(1):24\u20136. https:\/\/doi.org\/10.1093\/cvr\/cvaa139.","journal-title":"Cardiovasc Res"},{"key":"968_CR47","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.atherosclerosis.2020.09.021","volume":"313","author":"A Cordero","year":"2020","unstructured":"Cordero A, Santos-Gallego CG, Facila L, Rodriguez-Manero M, Bertomeu-Gonzalez V, Castellano JM, et al. Estimation of the major cardiovascular events prevention with Inclisiran. Atherosclerosis. 2020;313:76\u201380. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2020.09.021.","journal-title":"Atherosclerosis"},{"key":"968_CR48","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.amjcard.2020.08.018","volume":"134","author":"SA Khan","year":"2020","unstructured":"Khan SA, Naz A, Qamar Masood M, Shah R. Meta-analysis of inclisiran for the treatment of hypercholesterolemia. Am J Cardiol. 2020;134:69\u201373. https:\/\/doi.org\/10.1016\/j.amjcard.2020.08.018.","journal-title":"Am J Cardiol"},{"key":"968_CR49","unstructured":"Banach M. Guidelines of the PTL\/KLRwP\/PTK\/PTDL\/PTNT on the management of lipid disorders in Poland. Archives of Medical Science. 2021;In Press."},{"key":"968_CR50","unstructured":"National Institute for Health and Care Excellence (NICE). Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia. https:\/\/www.nice.org.uk\/guidance\/indevelopment\/gid-ta10703. Accessed June 2021."},{"key":"968_CR51","doi-asserted-by":"publisher","DOI":"10.2217\/fca-2020-0150","author":"J Brandts","year":"2020","unstructured":"Brandts J, Ray KK. Clinical implications and outcomes of the ORION Phase III trials. Future Cardiol. 2020. https:\/\/doi.org\/10.2217\/fca-2020-0150.","journal-title":"Future Cardiol"},{"key":"968_CR52","doi-asserted-by":"publisher","unstructured":"Gennemark P, Walter K, Clemmensen N, Reki\u0107 D, Nilsson CAM, Kn\u00f6chel J et al. An oral antisense oligonucleotide for PCSK9 inhibition. Sci Transl Med. 2021;13(593). https:\/\/doi.org\/10.1126\/scitranslmed.abe9117.","DOI":"10.1126\/scitranslmed.abe9117"},{"issue":"3","key":"968_CR53","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1056\/NEJMoa1905239","volume":"382","author":"S Tsimikas","year":"2020","unstructured":"Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, Tardif JC, Baum SJ, Steinhagen-Thiessen E, et al. Lipoprotein(a) reduction in persons with cardiovascular disease. N Engl J Med. 2020;382(3):244\u201355. https:\/\/doi.org\/10.1056\/NEJMoa1905239.","journal-title":"N Engl J Med"},{"issue":"3","key":"968_CR54","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1056\/NEJMoa1701329","volume":"377","author":"MJ Graham","year":"2017","unstructured":"Graham MJ, Lee RG, Brandt TA, Tai LJ, Fu W, Peralta R, et al. Cardiovascular and metabolic effects of ANGPTL3 antisense oligonucleotides. N Engl J Med. 2017;377(3):222\u201332. https:\/\/doi.org\/10.1056\/NEJMoa1701329.","journal-title":"N Engl J Med"}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-021-00968-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11883-021-00968-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-021-00968-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T11:53:16Z","timestamp":1632743596000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11883-021-00968-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,1]]},"references-count":54,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["968"],"URL":"https:\/\/doi.org\/10.1007\/s11883-021-00968-7","relation":{},"ISSN":["1523-3804","1534-6242"],"issn-type":[{"value":"1523-3804","type":"print"},{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,1]]},"assertion":[{"value":"2 August 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Henney declares no competing interests.Dr. Penson owns four shares in AstraZeneca PLC, and has received honoraria and\/or travel reimbursement for events sponsored by AKCEA, Amgen, AMRYT, Link Medical, Mylan, Napp and Sanofi.Dr. Banach\u2014speakers bureau: Amgen, Esperion, Herbapol, Kogen, KRKA, Novartis, Polpharma, Sanofi-Aventis, Servier, Teva, Viatris and Zentiva; consultant to Akcea, Amgen, Daichii Sankyo, Esperion, Freia Pharmaceuticals, Novo-Nordisk, Polfarmex, Sanofi-Aventis; grants from Amgen, Viatris, Sanofi and Valeant.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"69"}}